Terrible though the Covid-19 pandemic has been, it has presented commercial opportunities for a number of the UK’s smaller listed biotechs, such as Synairgen.
The respiratory drug discovery and development company was the latest to see a share price boost from an announcement related to the treatment of the dreaded coronavirus.
The shares surged 51 per cent after the company said lab tests of its inhaled interferon beta, which is being developed to treat people with severe effects of COVID, have shown 'potent antiviral activity' against two new variants of the SARS-CoV-2.
Terrible though the Covid-19 pandemic has been, it has presented commercial opportunities for a number of the UK’s smaller listed biotechs, such as Synairgen